#China #Chongqing #Botulinum Toxin #Retoxin #Claruvis Pharmaceutical

Claruvis Pharmaceutical's Revolutionary Launch

In an exciting development for the pharmaceutical industry, Claruvis Pharmaceutical Co., Ltd. has announced that the National Medical Products Administration (NMPA) in China has granted approval for its groundbreaking product, Retoxin®. This marks the world’s first approval of a recombinant botulinum toxin type A, introducing a new era in the production and application of neurotoxins.

A Shift Toward Innovation

Traditionally, botulinum toxins have been derived from the natural extraction of Clostridium botulinum, but Claruvis is pioneering a shift towards recombinant technology. This approach not only enhances the safety profile of the product by mitigating the biological risks associated with traditional production methods but also significantly improves purity and specificity, ensuring a more potent active component.

The approval of Retoxin® for the temporary improvement of moderate to severe glabellar lines in adults signals a significant advancement in both aesthetic applications as well as potential therapeutic uses. Through a meticulously designed recombinant process, Claruvis retains the essential 150 kDa neurotoxin structure while eliminating impurities previously encountered in traditional extraction practices.

Clinical Success

The multicenter, phase III clinical trial, which was randomized, double-blind, and placebo-controlled, showcased the efficacy of Retoxin®. The results exceeded expectations, demonstrating superior effectiveness, a favorable safety profile, and low immunogenicity, which highlights the promising advantages of recombinant technologies for both aesthetic and therapeutic applications.

Expanding Therapeutic Applications

Building on the success of Retoxin® for aesthetic use, Claruvis is also developing its applications in therapeutic contexts, particularly focusing on treating upper limb spasticity resulting from stroke or traumatic brain injury. With the completion of a successful phase II clinical trial, the company is actively recruiting participants for a phase III study across over twenty medical centers in China. This initiative aims to provide a safer and more effective treatment option for patients facing debilitating spasticity.

Contributing to Global Health

Dr. Yang, the Chief Scientific Officer at Claruvis Pharmaceutical, emphasized that this achievement represents not just a commercial milestone but validates the vision to develop next-generation botulinum neurotoxins characterized by increased purity, consistency, and safety.

Furthermore, Liu, the CEO, remarked that this approval is a critical step forward and underscores their commitment to advancing their innovative portfolio of recombinant botulinum toxins, ultimately broadening treatment options available to patients and healthcare professionals around the globe.

About Claruvis Pharmaceutical

Claruvis Pharmaceutical Co., Ltd., a subsidiary of MingMed Biotechnology, stands at the forefront of bio-pharmaceutical innovation focusing on the research, development, manufacturing, and marketing of recombinant botulinum toxin products. The company’s proprietary platforms have enabled the introduction of this first recombinant botulinum toxin type A, marking a transition from traditional methods to precision recombinant production. Claruvis is dedicated to delivering safer and higher-quality medicines for aesthetic and therapeutic indications worldwide.

This groundbreaking pharmaceutical achievement opens avenues for future treatments and pushes the boundaries of what’s possible within the biotechnology landscape. As Claruvis continues to innovate, the industry watches closely to see how these advancements will influence global healthcare practices.